drugset / Trial / NCT00200525

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

NCT00200525 ↗

Phase 3 Completed 60 enrolled Mylan Bertek Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.

Timeline

Start
2001-07
Primary completion
—
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Apomorphine Unknown — Subcutaneous

Indications